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Venous thromboembolism constitutes one of the main causes of death during the progression of a cancer. We previously dem-
onstrated that tissue factor (TF)-bearing cancer cell-derived microparticles accumulate at the site of injury in mice developing
a pancreatic cancer. The presence of these microparticles at the site of thrombosis correlates with the size of the platelet-rich
thrombus. The objective of this study was to determine the involvement of TF expressed by cancer cell-derived microparticles
on thrombosis associated with cancer. We observed that pancreatic cancer cell derived microparticles expressed TF, its inhibi-
tor tissue factor pathway inhibitor (TFPI) as well as the integrins avb1 and avb3. In mice bearing a tumor under-expressing TF,
a significant decrease in circulating TF activity associated with an increase bleeding time and a 100-fold diminished fibrin gen-
eration and platelet accumulation at the site of injury were observed. This was mainly due to the interaction of circulating can-
cer cell-derived microparticles expressing TFPI with activated platelets and fibrinogen. In an ectopic model of cancer,
treatment of mice with Clopidogrel, an anti-platelet drug, decreased the size of the tumors and restored hemostasis by pre-
venting the accumulation of cancer cell-derived microparticles at the site of thrombosis. In a syngeneic orthotopic model of
pancreatic cancer Clopidogrel also significantly inhibited the development of metastases. Together, these results indicate that
an anti-platelet strategy may efficiently treat thrombosis associated with cancer and reduce the progression of pancreatic can-
cer in mice.
Since its first clinical description by Armand Trousseau in
1865, the association between cancer and thrombosis has
been well documented.1 Venous thromboembolism (VTE),
defined as deep vein thrombosis and/or pulmonary embolism
(PE), occurs in 15–20% of patients with cancer.2 VTE consti-
tutes one of the main causes of death during the progression
of cancer (with a relative risk ranging from 4 to 7) and rep-
resents a major therapeutic issue. The risk of thrombosis is
increased in patients with digestive adenocarcinoma, pancre-
atic adenocarcinomas, lung or ovarian cancer and acute
promyelocytic leukemia.3–5 Among these cancers, throm-
boembolic diseases are the second most common cause of
death, accounting for 44% of deaths after the progression of
the cancer itself.6,7 Patients with cancer who develop a VTE
have a lower survival rate.8 Several studies have been per-
formed recently to understand the cellular mechanisms
involved in the development of thromboembolic events. The
pathogenesis of a thrombotic state is linked to the presence
of a tumor and is associated with the development of a
hypercoagulant state, referred to as coagulopathy that confers
numerous advantages to the cancer cells. Indeed, both the
activation of the coagulation cascade and the aggregation of
blood platelets around cancer cells protect these cells from
the immune system and facilitate their circulation in the
bloodstream and their adhesion at potential sites of metasta-
sis.9,10 In addition to its role in the activation of coagulation,
the TF/FVIIa complex also influences pathways that activate
cell-bound protease-activated receptors (PARs), leading to the
activation of inflammatory and angiogenic responses.11 These
processes lead to a model in which the presence of tissue fac-
tor (TF), the generation of thrombin and the activation of
platelets all directly participate in the progression of the can-
cer. In addition, the presence of TF and the activation of pla-
telets participate in the progression of the tumor.12 Thus, it is
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logical to hypothesis that treatment with anticoagulant or
antiplatelet drugs may prevent, in addition to coagulopathy,
progression of a tumor and formation of metastasis. How-
ever, in the absence of clear data in the literature, these drugs
are not indicated in the prevention of venous thromboem-
bolic events or in treatment for cancer.
We previously demonstrated the key role of TF-bearing
cancer cell-derived microparticles in thrombosis associated
with cancer.13 We found that both endogenously generated
and exogenously injected pancreatic cancer cell-derived
microparticles expressing TF (Panc02), but not their parental
tumor cells, accumulated at the site of injury in a P-selectin-
dependent manner. The presence of these microparticles
directly correlated with the size of the thrombus. Based on
these data, we hypothesized that treatment with anticoagulant
or antiplatelet drugs may prevent tumor progression and the
formation of metastases, in addition to coagulopathy. Here,
we showed in syngeneic ectopic and orthotopic mice models
that treatment with Clopidogrel prevented the binding of
cancer cell-derived microparticles to fibrinogen-platelets
aggregates at the site of thrombosis, thereby suppressing the
development of the tumor and reducing metastasis and the
extent of thrombosis associated with cancer.
Material and Methods
Mice
Wild-type C57BL/6J mice were obtained from Janvier Elevage
and were housed under standard conditions. All of the ani-
mal care and experimental procedures were performed as
recommended by the European Community guidelines and
were approved by the local ethical committee number 14
(number 11102012).
Antibodies and reagents
Rabbit anti-mouse TF IgG (Abcam, ab17375), rabbit anti-
mouse Tissue Factor Pathway Inhibitor (TFPI) IgG (Ameri-
can Diagnostica), Alexa Fluor 594-conjugated anti-rabbit IgG
(Life Technologies) and HRP-linked Ab anti-rabbit IgG (Cell
Signaling) were used in vitro for western blotting and immu-
nofluorescence. PE-conjugated hamster anti-mouse CD61,
hamster anti-mouse CD29, rat anti-mouse CD51 and appro-
priated isotypes controls were used to perform flow cytome-
try experiments (BD Bioscience). For the in vivo experiments,
a rat anti-mouse CD41 antibody (Emfret analytics), a rat
anti-mouse P-selectin antibody (BD Bioscience) and a mouse
anti-fibrin antibody were labeled and used as previously
described.14 R300 antibody used to deplete circulating plate-
lets was obtained from Emfret anaytics. Arg-Gly-Asp-Val
peptide was purchased from Polypeptide. The microparticles
were labeled using DIO (iodide of (dodecyl-4 aminostyryl)24
N- methylpyridium) VybrantTM kit (Molecular Probes).
Cell culture
The mouse pancreatic cancer cell line Panc02, originally
established by Corbett et al.15, was generously given to our
laboratory by Ruben Hernandez-Alcoceba (University of
Navarra, Pamplona, Spain). Panc02 cells and Panc02-GFP
cells13 were grown in RPMI-1640 medium (Life Technolo-
gies) supplemented with 10% FCS (PAA), 100 U/mL penicil-
lin (Life Technologies), 100 mg/mL streptomycin (Life
Technologies) and 0.1% fungizone (Life Technologies). The
cells were grown at 37C in a humidified atmosphere with
5% CO2.
Cell transfection
Panc02 cells were stably transfected with the pGL4.51[luc2/
CMV/Neo] vector (Promega), the pcDNATM 6.2-GW/
EmGFP-miR mock or the pcDNATM 6.2-GW/EmGFP-miR
Tissue Factor plasmids (Life Technologies) using Lipofect-
amine 2000 and PLUS reagent (Life Technologies) according
to the manufacturer’s recommendations (Life Technologies).
After 2 months of selection using G418. One clone was
selected based on its luminescence activity and was named
Panc02-Luci. Two other clones selected one coding for
miRNA directed against the tissue factor and associated with
the expression of the GFP, and a its control coding for
miRNA directed against a scramble were selected based on
their GFP expression and named Panc02-Low TF and
Panc02-HighTF, respectively.
Isolation of microparticles
The isolation of microparticles was performed as previously
described.13
Preparation of Platelets-Poor Plasma containing
microparticles
Blood was collected from tumor-free mice and mice bearing
a tumor in a citrate solution (ACD: 85 mM trisodium citrate,
67 mM citric acid, 111.5 mM glucose, pH 4.5) in the
What’s new?
Tissue factor (TF) plays a key role in coagulation and is capable of activating inflammatory and angiogenic responses, poten-
tially facilitating the progression of cancer. As a result, anticoagulant or antiplatelet drugs could be effective means of preven-
tion for tumor progression and metastasis. Here, pancreatic cancer cell-derived microparticles were found to express TF and
its inhibitor TFPI. The microparticles interacted with platelets, with effects on bleeding and platelet accumulation, in mice. In
cancer mouse models, treatment with the antiplatelet drug clopidogrel restored hemostasis, resulted in decreased tumor size,
and prevented the development of metastases.
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presence of 0.5 mM prostacyclin (PGI2; Calbiochem-Nova-
biochem) and 0.02 U/mL apyrase (Sigma-Aldrich). Citrated
blood was centrifuged at 200g for 12 min to obtain Platelets-
Rich Plasma (PRP). Platelets-Poor Plasma (PPP) was
obtained after centrifugation of PRP at 1,100g for 10 min,
following addition of PGI2 to prevent platelets activation.
PPP was then centrifuged at 7,000g for 3 min. Aliquots were
snap-frozen in liquid nitrogen and stored at 280C.
Flow cytometry
The expression of AnnexinV, GFP and the beta1, beta3 and
alphav subunits at the surface of Panc02 clones and their
microparticles was analyzed using a Gallios flow cytometer
(Beckman Coulter). The flow cytometry instrument settings
and microparticles gating were performed with Megamix
beads. Briefly, PPP or purified microparticles suspension were
incubated 40 min with FITC-annexin V and PE-anti mouse
antibodies (anti-CD29; anti-CD51 and anti-CD61). All the
data analyses were performed with the software Kaluza.
RT-PCR
The presence of TF mRNA in the Panc02-HighTF and
Panc02-LowTF clones was detected by RT-PCR (Promega).
Immunofluorescence
The cells were grown to 80% confluence in an eight-chamber
glass system (Thermo Fisher Scientific), washed with PBS,
and fixed for 30 min at 4C in PBS containing 2% parafor-
maldehyde. Once fixed, the cells were incubated for 1 hr with
blocking buffer (PBS, 1% BSA, 0.05% saponin) at room tem-
perature. Cell nuclei were labeled with 4’,6-diamidino-2-phe-
nylindole (DAPI), and the cells were incubated with or
without a TF antibody and with an Alexa Fluor 488-
conjugated secondary antibody. Between each step, the cells
were extensively washed with PBS. The stained cells were
visualized using a fluorescence microscope and analyzed
using SlideBook 5.0 software (3I).
PAGES and western blotting
SDS-PAGE (4–20%) and western blotting were performed as
previously described.16
TF and TFPI activity assay
A chromogenic assay (Actichrome TF and TFPI activity assay;
American Diagnostica) was used to analyze TF and TFPI activ-
ity according the manufacturer’s instructions. The absorbance
was read at 405 nm with a microplate reader (MR5000; Dyna-
tech). The TF and TFPI concentrations were determined by
interpolation from a standard curve constructed using different
amounts of lipidated TF and TFPI standards.
Flow chamber
All the flow chamber experiments were performed with the
IBIDI pump system. Briefly, l-Slides-ibidi-treated were
coated with fibrinogen or PBS for 30 min (40 lg/mL; Sigma
Aldrich). Labeled microparticles (2 3 105) were infused in m-
slides. Shear rate were applied through an air-driven continu-
ous flow pump system controlled by a computer with the
PumpControl Software.17
Ectopic tumors induction
Panc02 cells were cultured to 80% confluence and, once in
the exponential growth phase, were washed three times with
PBS and briefly exposed to nonenzymatic cell dissociation
buffer (Life Technologies) to dislodge the cells. The cells were
carefully washed three times, resuspended in PBS, and diluted
to the desired concentration. Five-week-old C57BL/6 mice
were injected subcutaneously in the right flank with a tumor
cell suspension (106 cells in 100 mL of PBS2/2). When the
tumor became palpable (0.2 cm), measurements in two
dimensions were performed with a caliper, and the volume
of each tumor was calculated according to the formula for
the volume of an ellipsoid: p/6 3 a(b2), where a is the largest
diameter and b the smallest diameter of the tumor.
Orthotopic tumors induction
Panc02-Luci cells were cultured to 80% confluence and, once
in the exponential growth phase, were washed three times
with PBS and briefly exposed to nonenzymatic cell dissocia-
tion buffer to dislodge the cells. The cells were carefully
washed three times, resuspended in RPMI medium and
diluted to the desired concentration. The Panc02-Luci cells
were kept on ice until injection. Five-week-old C57BL/6 mice
were anesthetized with an intraperitoneal injection of keta-
mine (125 mg/kg; Panpharma), xylazine (12.5 mg/kg; Bayer)
and atropine (0.25 mg/kg; Lavoisier). The peritoneal cavity
was opened, and a mixture containing a tumor cell suspen-
sion (2 3 106 cells in 50 mL of RPMI medium) and 50 mL of
Matrigel (BD Bioscience) was injected into the head of the
pancreas, as previously described.18 Temgesic was subcutane-
ously administered to mice (0.025 mg/kg) just after the sur-
gery and 24 hr later. Mice were daily observed and treated
with Buprenorphin (up to 2.5 mg/kg) as soon as distinctive
pain signs were detected.
Clopidogrel, low-molecular-weight heparin and aspirin
treatment
Two days after the induction of ectopic tumors and 7 days after
induction of orthotopic tumors, the mice were randomly
divided into several groups (with at least eight mice/group).
For the duration of the experiment, the mice received daily per
os 200 mL of 0.09% NaCl (control group), Clopidogrel at 8 mg/
kg in a final volume of 200 mL (Clopidogrel group) or Aspirin
at 10 mg/kg in a final volume of 200 mL (Aspirin group).
Another group of mice received 0.1 mg/kg low molecular
weight heparin (LMWH) subcutaneously (LMWH group).
In vivo bioluminescence imaging
Prior to the in vivo imaging, the mice were anesthetized with
an intraperitoneal injection of ketamine (125 mg/kg;
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Figure 1. Involvement of TF expressed at the surface of Panc02 cells on hemostasis and thrombosis in a syngeneic ectopic model of pan-
creatic cancer in mice. (a) Tail bleeding times for tumor-free mice (N512), mice bearing Panc02-HighTF ectopic tumors (N511) and mice
bearing Panc02-LowTF ectopic tumors (N59). (b) Number of Annexin-V positive microparticles detected by FACS-analysis present in the
plasma of tumor-free mice (N56), mice bearing Panc02-HighTF ectopic tumors (N57) and mice bearing Panc02-LowTF ectopic tumors
(N56). (c) Concentration in active tissue factor present in the plasma of tumor-free mice (N58), mice bearing Panc02-HighTF ectopic
tumors (N58) and mice bearing Panc02-LowTF ectopic tumors (N58). (d) Representative images of thrombus formation obtained by intra-
vital microscopy in tumor-free mice or mice bearing Panc02-HighTF or Panc02-LowTF tumors. Following laser-induced injury, the kinetics of
thrombosis were evaluated based on the platelet accumulation (depicted in green) at different time points during thrombus formation by
the infusion of a rat anti-mouse platelet CD41 antibody (Emfret Analytics). (e) The graph depict the median integrated fluorescence intensity
of platelets as a function of time in thrombi after laser-induced injury in tumor-free mice (43 thrombi in 4 mice), Panc02-HighTF (42 thrombi
in 4 mice) and Panc02-LowTF mice (46 thrombi in 4 mice). *p<0.05; **p<0.01; ***p<0.001. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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Panpharma), xylazine (12.5 mg/kg; Bayer) and atropine
(0.25 mg/kg; Lavoisier) and were given D-luciferin (Molecular
Probes) by intraperitoneal injection (150 mg/mL). The biolu-
minescence signal of the tumor was measured 20 days after
the injection of the tumor cells using an in vivo biolumines-
cence imaging system (Biospace, Paris, France). The lucifer-
ase bioluminescence activity was measured for 10 min first
on the ventral face of the animal, and next on the spleen, the
bowel, the lungs and the kidneys using a Photon Imager
(Biospace).
Intravital microscopy and laser-induced injury
Intravital video microscopy of the cremaster muscle microcir-
culation was performed as previously described using Slide-
Book (Intelligent Imaging Innovation).16 Vessel wall injury
was induced with a MicroPoint Laser System (Photonics
Instruments) focused through the microscope’s objective, par-
focal with the focal plane and aimed at the vessel wall, as
previously described.19 The analyses were performed using
SlideBook software as described previously by Dubois et al.20
Tail bleeding time
Mouse tail bleeding times were determined as previously
described.16 The investigator was blinded to the genotype or
to treatments of the mice. Briefly, a 1- to 3-mm portion of
the distal tail was removed from a 6- to 8-week-old mouse;
the tail was immersed in isotonic saline (37C), and the time
to complete cessation of blood flow recorded. The bleeding
time was monitored for a maximum of 10 min.
Statistics
For in vitro experiments, significance was determined using
the paired two-tailed Student’s t test. For the in vivo experi-
ments, significance was determined using Wilcoxon’s rank-
sum test as previously described.13,16,19,20 For the measure of
the tumor volume, significance was determined using Mann–
Whitney test. The differences were considered to be signifi-
cant at p< 0.05.
Results
Knockdown of TF expressed at the surface of Panc02
affects tumor growth, hemostasis and thrombosis in a
syngeneic ectopic model of pancreatic cancer in mice
Tissue factor (TF) is both a main effector of the coagulation
cascade and a protein involved in the development of solid
tumors.21 To determine the involvement of TF expressed by
cancer cells, in thrombosis associated with cancer, we devel-
oped two different stables clones as described in “Material and
Methods” section named Panc02-LowTF and Panc02-HighTF.
The reductions in the expression of TF determined by RT-PCR
and immunofluorescence were 85 and 95%, respectively, in the
Panc02-LowTF cells in comparison with the Panc02-HighTF
cells (Supporting Information Figs. 1a and 1b). Although the
growth characteristics and the total number of microparticles
expressed by the two transfected cell clones (Supporting Infor-
mation Figs. 2a and 2b) were similar, the activity of TF was
decreased by up to 25% in the Panc02-LowTF cells (Supporting
Information Fig. 2c). As previously described in xenogeneic
models of cancers,22 when using the Panc02-LowTF cells, the
growth of the tumors in mice was reduced by 75% in compari-
son with the growth of tumors in mice injected with Panc02-
HighTF cells (Supporting Information Figs. 3a and 3b).
Together, these results indicate that the Panc02-LowTF and
Panc02-HighTF clones can be used as models to study the
effects of TF expression by cancer cells and cancer cell-derived
microparticles on thrombosis.
To understand the contribution of TF expressed by cancer
cells to the hemostatic process in vivo, we explored its effect
on primary hemostasis by comparing the bleeding times of
mice bearing Panc02-HighTF or Panc02-LowTF tumors and
wild-type mice. As previously demonstrated,13 the bleeding
time was significantly reduced for mice bearing Panc02-
HighTF tumors in comparison with wild-type mice. How-
ever, although Panc02-LowTF-bearing mice exhibited no evi-
dence of spontaneous bleeding or hemorrhage, the median
time to bleeding cessation was significantly prolonged
(p< 0.0002) in these mice compared with wild-type mice
(Fig. 1a). This effect was not attributed to alterations in the
platelet count, as wild-type mice injected with Panc02-
HighTF or Panc02-LowTF cells had similar platelet numbers
(data not shown). However, although the quantity of circulat-
ing microparticles was identical is mice bearing a Panc02-
Low and HighTF tumor (Fig. 1b), the activity of plasmatic
TF was significantly decreased when the protein was knock-
down from the cancer cells (Fig. 1c).
We next examined the kinetics of arteriolar thrombus
development in real time in the cremaster microcirculation of
wild-type mice bearing Panc02-LowTF or Panc02-HighTF
tumors or no tumors. Thrombus formation was initiated by
laser-induced injury of the arteriolar vessel wall. In tumor-
free mice, platelets adhered and accumulated at the site of
injury. The thrombus increased in size rapidly between 15
and 90 sec after injury and then decreased in size and stabi-
lized at 3–4 min after injury (Figs. 1d and 1e), as previously
observed.13 Platelets accumulated more rapidly at the site of
injury and the thrombus reached a larger size in mice with
Panc02-HighTF tumors than in tumor-free mice. Surpris-
ingly, in mice with tumors induced by Panc02-LowTF cells,
the rates of platelet accumulation at the sites of injury were
significantly slower in comparison with tumor-free mice
(Figs. 1d and 1e). Together, our results indicate that the spe-
cific inhibition of TF expression by cancer cells and their
microparticles may affect hemostasis and thrombosis in mice
even though the tumor is still present.
Treatment with Clopidogrel reduces thrombosis and
inhibits tumor growth without inducing prolonged
bleeding time
We next compared the effects of an inhibitor of platelet acti-
vation, Clopidogrel, and an inhibitor of the activation of the
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coagulant cascade, LMWH, on tumor growth and thrombosis
associated with cancer. The concentrations of the drugs used
were calculated to induce a 50% reduction in thrombus for-
mation following laser-induced injury in healthy mice (data
not shown). In vitro, Clopidogrel and LMWH did not affect
the growth of the Panc02 clones (data not shown). The two
drugs were administered daily to the mice and the treatment
started 2 days after the injection of the cancer cells. A signifi-
cant decrease in the tumor growth rate was observed in mice
treated with these two drugs in comparison with untreated
mice from day 12 to day 20 after injection of the tumor cells
(Fig. 2a). Twenty days following the injection of the cancer
cells, the volume of the tumor was reduced by more than
80% in the treated groups, with a mean volume of 0.86 mm3
for the control group versus 0.13 and 0.10 mm3 when
LMWH or Clopidogrel were used, respectively (Fig. 2b).
However, the tumor growth rates (Fig. 2c) and the volumes
of the tumors 20 days post-injection (Fig. 2d) were not sig-
nificantly different in mice treated with Clopidogrel.
We next compared the kinetics of thrombosis following
laser-induced injury in mice treated with Clopidogrel or
LMWH and bearing Panc02-HighTF tumors for 20 days. The
treatment with LMWH significantly reduced the rate of
thrombus formation in mice bearing a tumor in comparison
with tumor-free mice (Fig. 3a). In contrast, treatment with
Clopidogrel induced a phenotype similar to that observed in
tumor-free mice (Fig. 3b). These results indicate that a direct
inhibition of platelet activation may constitute an efficient
strategy to treat thrombosis associated with cancer.
Clopidogrel prevents the accumulation of cancer cell-
derived microparticles at the site of thrombosis
Previously result from our group demonstrated that can-
cer cell-derived microparticles accumulation at the site of
thrombosis is responsible for the thrombotic phenotype
observed in mice with cancer.13 We hypothesis that a treat-
ment with an antiplatelet drug may affect the accumulation
of cancer cell-derived microparticles at the site of thrombosis.
Before injury but after their infusion into the bloodstream,
Figure 2. Treatment with Clopidogrel reduces tumor growth. (a, b) The growth of the tumors over time (a) and mean volume of the tumors
at day 20 (b) were evaluated in mice bearing ectopic tumors induced by Panc02-HighTF cells and treated or not (N510) with Clopidogrel
(N59, 8 mg/kg daily) or low-molecular-weight heparin (N511, 0.5 mg/kg mouse, daily). (c, d) The kinetics of tumor growth (c) and mean
tumor volume at day 20 (d) for mice ectopically injected with Panc02-LowTF cells (N512) or Panc02-HighTF cells (N510) or injected with
Panc02-LowTF cells and treated with Clopidogrel (N513). **p<0.01; ***p<0.001.
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exogenous labeled cancer cell-derived microparticles were
detected in the cremaster microcirculation of untreated and
Clopidogrel-treated mice (Fig. 4a, left panel). However, fol-
lowing the injury, cancer cell-derived microparticles accumu-
lated at the site of the thrombus formation only in untreated
mice (Fig. 4a, right panel), suggesting that treatment by Clo-
pidogrel prevents the accumulation of cancer cell-derived
MPs at the site of thrombosis. These results were confirmed
by tracking endogenously shed cancer-cell derived micropar-
ticles using Panc02-GFP cells injected subcutaneously in a
mouse.13 Endogenous microparticles circulate in the blood-
stream of a mouse bearing a Panc02-GFP tumor and accu-
mulate at the site of injury (Fig. 4b, left panel). The
treatment of mice with Clopidogrel prevents this interaction,
although microparticles were still detected in the bloodstream
(Fig. 4b, right panel).
To determine the molecular pathways involved in the accu-
mulation of cancer-cell derived microparticles at the site of
thrombosis, we next look for the proteins expressed at their
surface. In addition to PSGL-1,13 the integrin subunits CD51
(av), CD29 (b1) and CD61 (b3) were identically highly
expressed at the surface of the Panc02-low and highTF MPs
(Fig. 4c). The number of microparticles expressing CD29,
CD51 and CD61 produced per cell was similar between the
Figure 3. Treatment with Clopidogrel reduces thrombosis without affecting the bleeding time. (a) Representative images of thrombus forma-
tion in tumor-free mice and mice bearing Panc02-HighTF tumors with or without treatment with Clopidogrel or LMWH. (b) The median maxi-
mum integrated fluorescence intensity of the platelet thrombi in tumor-free mice (43 thrombi in 4 mice) or in mice bearing Panc02-HighTF
tumors in the absence (46 thrombi in 4 mice) or presence of treatment with Clopidogrel (44 thrombi in 4 mice) or LMWH (38 thrombi in 3
mice). **p<0.01; ***p<0.001. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Panc02-Low and -HighTF (Fig. 4e). These results suggest that
Panc02-derived microparticles may directly bind to fibrinogen
at the site of thrombosis. Under in vitro flowing conditions, the
addition of RGDV, a competitive inhibitor of the interaction
between the avb1/b3 integrins and their ligands, inhibited the
adhesion of Panc02-Low and -HighTF microparticles to fibri-
nogen (Fig. 5a). This result was confirmed in vivo, following
laser-induced injury (Fig. 5b, upper panel). In mice bearing a
Panc02-GFP tumor, depletion of circulating platelets by injec-
tion of R300 antibody23 prevented the adhesion of circulating
Panc02-GFP microparticles at the site of injury (Fig. 5b, low
panel). Last, when mice bearing Panc02 tumors were treated
with Clopidogrel, the quantity of P-selectin, mainly expressed
by activated platelets present at the site of injury was fourfold
less important in comparison with untreated mice (Fig. 5c).
Taking together these results indicate that Panc02 cancer cell-
derived microparticles firmly adhere at the site of injury to
fibrinogen present on activated platelets forming a thrombus.
Figure 4. Clopidogrel prevents the avb1- and avb3-dependent accumulation of cancer cell-derived microparticles at the site of thrombosis.
(a, b) Representative images of exogenously labeled and infused Panc02 microparticles in tumor-free mice (a) and endogenously formed
circulating Panc02-GFP microparticles in mice bearing an ectopic Panc02-GFP tumor (b) (in green) before and after injury in non-treated or
Clopidogrel treated mice (observed in almost three independent experiments). (d) Representative flow cytometry analysis of CD29 (b1),
CD51 and CD61 (b3) expression at the surface of Panc02-High and -Low TF cells. (e) Number of microparticles expressed by 5 3 108
Panc02-High and -Low TF cells and double positive for Annexin V and CD29, CD51 or CD61. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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Interestingly, Panc02-high and lowTF cancer cell-
derived microparticles express both TF13 and TFPI (Fig.
6a), a biological inhibitor of the coagulation cascade, in an
active form, as demonstrated by the assessment of the TFPI
activity present at the surface of the Panc02-LowTF and
Panc02-HighTF cells (Fig. 6b). We next compared fibrin
generation at the site of injury in Panc02-HighTF and
Panc02-LowTF cancer mice in the presence and absence of
Clopidogrel. In wild-type mice, as previously described,24
fibrin deposition increased during the first 5 min after
injury. This deposition of fibrin at the site of laser-induced
injury was significantly greater (p< 0.01) in mice following
Figure 5. Panc02-derived microparticles bind to fibrinogen and platelets in vitro and in vivo. (a) Representative pictures (Left panel) or
median number (right panel, median of three independent experiments) of adherent microparticles on a fibrinogen matrix in in vitro flow
experiments performed after injection of 2 3 105 Panc02-HighTF (upper panel) and Panc02-LowTF (lower panel) microparticles in absence
(left panel) or presence of RGDV (5 mg/mL). Microparticles are depicted in green (603 objective). (b) Representative pictures (left panel)
and integrated fluorescence intensity (right panel) of Panc02-GFP microparticles accumulating at the site of injury in absence or presence of
RGDV (10 mg/kg) or R-300 (2 mg/g). Representative of four independent experiments per condition. (c) Representative image of P-selectin
accumulation (in green) in tumor-free mice treated with LMWH (c, top panel) or Clopidogrel (c, bottom panel) (observed in almost three
independent experiments). The median maximum integrated fluorescence intensity of P-selectin accumulating in wild-type mice treated with
LMWH or Clopidogrel (41 thrombi in 4 mice for each condition). **p<0.01. [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
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the injection of Panc02-HighTF cells than in wild-type
mice. The treatment of these mice with Clopidogrel
reduced the production of fibrin to a level comparable to
that observed in wild-type mice (Figs. 6c and 6d). When
the TF expression was knocked down from Panc02, the
production of fibrin was strongly reduced (Figs. 6c and
6d) and the plasmatic activity of TFPI was significantly
increased (Fig. 6e). We concluded that when cancer cells
and cancer cell-derived microparticles express active TF,
their incorporation to a growing thrombus via the binding
of fibrinogen present on platelets participates in the gen-
eration of a thrombotic phenotype. When TF expression
by cancer cells is knocked down, cancer cell microparticles
are still incorporated at the site of thrombus formation,
Figure 6. Inhibition of fibrin generation in mice bearing Panc02-LowTF tumors by cancer cell-derived microparticles expressing TFPI. (a)
Western blot analysis of TFPI expression in Panc02-HighTF or Panc02-LowTF cells and microparticles (MP) extracts (80 mg/well). (b) TFPI
activity (in units/mL) in Panc02-HighTF and Panc02-LowTF cells (mean of three independent experiments). (c) Representative image of fibrin
accumulation at the site of laser-induced injury in tumor-free mice or mice bearing Panc02-High or Panc02-LowTF tumors and treated with
Clopidogrel or left untreated. (d) Median integrated fluorescence intensity due to fibrin generation in tumor-free mice or mice bearing a
Panc02-HighTF or Panc02-LowTF tumors and treated or not by Clopidogrel (44 thrombi in 4 mice for each condition). (e) Plasmatic TFPI
activity (in units/mL) in mice bearing a Panc02-HighTF and Panc02-LowTF tumor (mean of three independent experiments). *p<0.05;
**p<0.01. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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but there is reduced activation of TF, thus inhibiting
fibrin generation and thrombus formation by bringing
TFPI to the site of injury. A treatment by Clopidogrel
prevents the accumulation of cancer cell-derived micro-
particles by inhibition of platelets.
Aspirin and Clopidogrel prevent tumor growth
and reduce metastasis in a syngeneic orthotopic
model of pancreatic cancer
Based on our observations, we hypothesized that the inhibi-
tion of platelet activation to reduce both thrombosis
Figure 7. Quantification of tumor growth and metastasis generation in a syngeneic orthotopic model of pancreatic cancer with or without
Clopidogrel or Aspirin treatment. (a, left panel) Representative images showing the bioluminescence signal at day 15 and day 35 (a, right
panel). The graph depicts the average of the tumor growth of bioluminescent orthotopic pancreatic cancer in mice as function of time. (b,
left panel) Representative image of organs metastasis, (b, right panel) the pie chart represents the percentage of the bioluminescence in
different organs (bowel, kidneys, lungs and spleen) of wide-type mice ortopically implanted with panc02-HightTF. (c, left panel) Representa-
tive image of the bioluminescence signals of Panc02-HighTF tumors treated with Clopidogrel or Aspirin or left untreated at day 20. (c, right
panel) The graph represents the average bioluminescence signal intensity for mice ortopically implanted with panc02-HightTF non treated
(control; N58) or treated with ether Clopidogrel (N511) or Aspirin (N510). (d) Percent bioluminescence by type of metastasis (bowel,
kidney, lung and spleen). This experiment was performed in six mice per group. *p<0.05. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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associated with cancer and tumor growth could constitute an
interesting therapeutic strategy to treat cancer and thrombo-
sis. To test this hypothesis, we developed a syngeneic ortho-
topic model of pancreatic cancer by stably transfecting
Panc02 cells with a gene encoding luciferase before implanta-
tion into the pancreases of wild-type mice.18 This cellular
clone was named Panc02-Luci. The development of the
tumors and the formation of metastasis were monitored over
a period of up to 2 months in mice. Using an in vivo imag-
ing system based on a bioluminescence technology, we were
able to noninvasively monitor and measure the orthotopic
tumor growth and the development of metastases in the
whole mouse. Figure 7a shows the growth of the Panc02-
Luci tumors in wild-type mice. The quantity of Panc02-Luci
cells present in the mice increased over time (Fig. 7a, left
panel), indicating an increase in the tumor size that can be
quantified by luminescence (Fig. 7a, right panel). At the end
of the experiment, we detected and quantified the presence of
luciferase-expressing tumor cells in each harvested organ, and
we observed that wild-type mice developed metastases in the
bowel, spleen and kidneys and, after 30 days, in the lungs
(Fig. 7b, left panel). The greatest luminescence intensity, cor-
responding to the number of Panc02-Luci cells, was observed
in the bowel (Fig. 7b, right panel). In vitro, Aspirin and Clo-
pidogrel did not affect the growth of the Panc02-Luci clone
(data not shown). In vivo, when mice were treated with Clo-
pidogrel or Aspirin daily for 28 days, the growth of the pri-
mary tumor was significantly reduced; 35 days after the
injection of the Panc02-Luci cells into the pancreas, a signifi-
cant difference in the bioluminescence signal was observed
between control and Clopidogrel- or Aspirin-treated mice
(Fig. 7c, left panel). This difference was observed when the
whole-body luminescence signals were detected (Fig. 7c, right
panel) as well as when we focused on the development of
metastases (Fig. 7d). Although metastases were detected in
the lungs and spleens of 100% of the untreated mice, only
40% of the mice treated with Clopidogrel or Aspirin devel-
oped metastases in these organs (Fig. 7d). Together with the
effects of anti-platelet drugs on thrombosis, these results indi-
cate that Clopidogrel and Aspirin may represent promising
therapeutic drugs to limit thrombosis and reduce the devel-
opment of tumors and metastases.
Discussion
The goal of our study was to determine the effect of anti
coagulant and anti platelet strategies on thrombosis and
tumor development in mice developing a pancreatic cancer.
We show that inhibition of the expression of TF by cancer
cells leads to a decrease of platelet-rich thrombus formation
and strongly diminishes the growth of the tumor. The knock-
down of TF expressed by cancer cells also strongly affects the
bleeding time and the activation of the blood coagulation cas-
cade, mainly via the interaction of cancer cell-derived micro-
particles expressing TFPI, avb1 and avb3 with fibrinogen
and platelet aggregates. When platelet activation is directly
inhibited using Clopidogrel, thrombus formation is reduced
without affecting the bleeding time and cancer cells derived
microparticles do not accumulate at the site of injury. Treat-
ment by Clopidogrel also significantly reduces the growth of
the tumor. Although the models and the type of cancer stud-
ied are different, these results are in accordance with the pre-
vious studies showing an effect of Clopidogrel treatment on
the growth of hepatocellular carcinoma or mammary carci-
noma.25,26 Altogether these results suggest that an antiplatelet
strategy may be efficient to reduce the tumor growth inde-
pendently to the type of cancer. We showed in this study in
a syngeneic orthotopic model of pancreatic cancer that, two
antiplatelet drugs, Clopidogrel and Aspirin, significantly
reduce the size of the tumor and inhibit the development of
metastases. Together, our results indicate that an anti-platelet
strategy may efficiently treat thrombosis associated with can-
cer and reduce the progression of pancreatic cancer in mice.
In addition to its functions in coagulation, TF has also
been reported to induce the transcriptional activation of differ-
ent growth factors, including VEGF, following the phosphoryl-
ation and binding of its cytoplasmic tail to filamin.27,28 This
intracellular pathway may also participate in the growth of the
tumor and angiogenesis.29 Furthermore, TF expression has
also been reported to influence the motility, survival and pro-
liferation of cancer cells via the activation of PAR-1 and PAR-
2,30,31 although in the present study, the proliferation of
Panc02 cells was not affected by the inhibition of TF expres-
sion. Cancer cells may directly activate platelets by secreting
ADP, thromboxane A2 and MMP-2 (matrix metalloproteinase
2) and by expressing platelet ligands, such as PSGL-1, on their
surfaces.32–34 This leads to the aggregation of platelets in the
bloodstream around cancer cells, a process that has been
reported to protect cancer cells from destruction by the
immune system and from blood shear stress. This aggregation
also facilitates interactions of cancer cells with the endothe-
lium.35 However, the direct involvement of these platelet ago-
nists was not demonstrated in vivo in an orthotopic syngeneic
mouse model. When mice were treated with LMWH, a
decrease in tumor development similar to that obtained when
pathological TF expression was knocked down was observed.
Additionally, treatment with Clopidogrel did not significantly
affect the growth of the tumors in the Panc02-LowTF group
or in the Panc02-HighTF group treated with LMWH (data
not shown). These results strongly suggest that the activation
of platelets is involved in the growth of the tumor and that
the main activator of platelets is TF expressed by cancer cells,
not ADP or thromboxane A2. These secondary agonists may
be involved when secreted as a consequence of platelet activa-
tion generated by thrombin through a TF-dependent pathway.
Lastly, these agonists may not play an important role
directly in the growth of tumors but may play important
roles in the formation of metastases when cancer cells are
present in the bloodstream.
The injection of LMWH was recently described as a
potent treatment for thrombosis associated with cancer.
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Indeed, LMWH acts on the coagulation cascade and prevents
interactions between P-selectin and its ligands.36 Different
clinical studies have been performed, but to date, none have
shown a clear benefit of such treatment for thrombosis asso-
ciated with cancer. We showed that the use of LMWH in
mice affected not only thrombosis but also hemostasis. In
humans, different studies have shown an increased risk of
bleeding associated with treatment with LMWH. This
increased risk may be due to the presence of TFPI on cancer
cell-derived microparticles. Surprisingly, the use of antiplate-
let drugs to treat thrombosis associated with cancer has never
been evaluated in a syngeneic orthotopic mice model. Our
results for the effects of Clopidogrel on tumor growth were
similar to those observed when LMWH was injected or when
TF expression was knocked down. However, Clopidogrel, at
the concentration used, did not induce a hemorrhagic-like
phenotype in mice, as shown by the observed kinetics of pla-
telet and fibrin generation. We have previously shown that
circulating TF-bearing cancer cell-derived microparticles play
an important role in thrombosis associated with cancer.13
Anti-platelet drugs, but not LMWH, may efficiently affect
thrombosis induced by cancer cells without affecting hemo-
stasis by limiting the interactions of circulating cancer cell-
derived microparticles. Furthermore, in a syngeneic ortho-
topic model of pancreatic cancer, Clopidogrel and Aspirin
strongly inhibited the formation of metastasis. Recently, a
meta-analysis demonstrated the short-term benefit of daily
Aspirin on cancer incidence.37 This finding has been con-
firmed by observational studies showing that the regular use
of Aspirin reduces the long-term risk of several cancers and
the risk of distant metastasis.38 However, in two randomized
studies, there were no benefits of low-dose Aspirin in the pri-
mary prevention of cancer.39,40 Here, we observed similar
effects for Aspirin and Clopidogrel. However, the molecular
pathways involved in the effects of Aspirin and Clopidogrel
on the reductions in tumor development and metastasis
remain unidentified.
Together, these results strongly suggest that the use of
anti-platelet drugs may be an efficient alternative strategy to
the use of LMWH to treat patients suffering from thrombosis
associated with cancer and to limit development of tumors.
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